Influence of particle size on the distributions of liposomes to atherosclerotic lesions in mice

Drug Development and Industrial Pharmacy

Volumn 32, Issue 1, 2006, Pages 125-135

  Chono, Sumio ^a   Tauchi, Yoshihiko ^a   Morimoto, Kazuhiro ^a  

^a HOKKAIDO INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

Atherogenic mice; Drug carrier; Liposomes; Macrophages and foam cells; Particle size

Indexed keywords

CHOLESTEROL; DICETYL PHOSPHATE; DRUG CARRIER; LIPOSOME; PHOSPHATIDYLCHOLINE; POLYCARBONATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTICLE; ATHEROSCLEROSIS; CIRCULATION; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG UPTAKE; FOAM CELL; LIVER; MACROPHAGE; MALE; MOUSE; NONHUMAN; PARTICLE SIZE; SPLEEN;

ANIMALS; ATHEROSCLEROSIS; DRUG CARRIERS; FOAM CELLS; LIPOSOMES; MACROPHAGES; MALE; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED ICR; PARTICLE SIZE; TISSUE DISTRIBUTION;

EID: 32344437398     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040500390645     Document Type: Article

References (34)

1. Asai, K., Funai, C., Hayashi, T., Yamada, K., Naito, M., Kuzuya, M., Yamada, K., Yoshimine, N., & Kuzuya, F. (1993). Dexamethasone-induces suppression of aortic atherosclerosis in cholesterol-fed rabbits. Arterioscler. Thromb., 13, 892-899.
2. Bailey, J. M., & Butler, J. (1973). Anti-inflammatory drugs in experimental atherosclerosis. I. Relative potencies for inhibiting plaque formation. Atherosclerosis, 17, 515-522.
3. Bailey, J. M., Makheja, A. N., Butler, J., & Salata, K. (1979). Anti-inflammatory drugs in experimental atherosclerosis. Part 4. Inhibition of atherosclerosis in vivo and thromboxane synthesis and platelet aggregation in vitro. Atherosclerosis, 32, 195-203.
4. Bangham, A. D., Standish, M. M., & Watkins, J. C. (1965). Diffusion of univalent ions across the lamellae of swollen phospholipids. J. Mol. Biol., 13, 238-252.
5. Branford, M. M. (1976). A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72, 248-254.
6. Chono, S., Tauchi, Y., Deguchi, Y., & Morimoto, K. (2005). Efficient drug delivery to atherosclerotic lesions and the anti-atherosclerotic effect by dexamethasone incorporated into liposomes in atherogenic mice. J. Drug Target, 13, 267-276.
7. Derksen, J. T., Morselt, H. W., & Scherphof, G. L. (1987). Processing of different liposomal markers after in vitro uptake of immunoglobulin-coated liposomes by rat liver macrophages. Biochim. Biophys. Acta, 931, 33-40.
8. Funato, K., Yoda, R., & Kiwada, H. (1992). Contribution of complement system on destabilization of liposomes composed of hydrogenated egg phosphatidylcholine in rat fresh plasma. Biochim. Biophys. Acta, 1103, 198-204.
9. Harashima, H., Sakata, K., Funato, K., & Kiwada, H. (1994). Enhanced hepatic uptake of liposomes through complement activation depending on the size of liposomes. Pharmaceu. Res., 11, 402-406.
10. Harashima, H., Houng, T. M., Ishida, T., Manabe, Y., Matsuo, H., & Kiwada, H. (1996). Synergistic effect between size and cholesterol content in enhanced hepatic uptake clearance of liposomes through complement activation in rats. Pharmaceu. Res., 13, 1704-1709.
11. Hatch, F., & Less, R. S. (1968). Practical methods for plasma lipoprotein analysis. Adv. Lipid Res., 6, 2-63.
12. Hodis, H. N., Amartey, J. K., Crawford, D. W., Wickham, E., Sharma, R. C., & Blankenhorn, D. H. (1991). Relationship of arterial wall uptake of radiolabeled liposomes to the presence of monocyte/macrophage cells in the hypertensive and atherosclerotic arterial wall. Atherosclerosis, 87, 109-117.
13. Houng, T. M., Harashima, H., & Kiwada, H. (1998). Complement dependent and independent liposome uptake by peritonea macrophages: cholesterol content dependency. Biol. Pharm. Bull., 21, 969-973.
14. Houng, T. M., Harashima, H., & Kiwada, H. (1999). In vivo studies on the role of complement in the clearance of liposomes in rats and guinea pigs. Biol. Pharm. Bull., 22, 515-520.
15. Hsu, M. J., & Juliano, R. L. (1982). Interactions of liposomes with the reticuloendothelial system. II: Nonspecific and receptor-mediated uptake of liposomes by mouse peritoneal macrophages. Biochim. Biophys. Acta, 720, 411-419.
16. Kajikawa, M., Ohta, T., Takase, M., Kawase, K., Shimamura, S., & Matsuda, I. (1994). Lactoferrin inhibits cholesterol accumulation in macrophages mediated by acetylated or oxidized low-density lipoproteins. Biochim. Biophys. Acta, 1213, 82-90.
17. Kawakami, S., Munakata, C., Fumoto, S., Yamashita, F., & Hashida, M. (2001). Novel galactosylated liposomes for hepatocyte-selective targeting of lipophilic drugs. J. Pharm. Sci., 90, 105-113. 2001.
18. Kelley, J. L., Suenram, C. A., Rozek, M. M., Schaffer, S. A., & Schwartz, C. J. (1988). Influence of the acyl-CoA: cholesterol O-acyltransferase inhibitor, CL 277082, on cholesteryl ester accumulation in rabbit macrophage-rich granulomas and hepatic tissue. Biochim. Biophys. Acta, 960, 83-90.
19. Makheja, A. N., Bloom, S., Muesing, R., Simon, T. M., & Bailey, J. M. (1989). Anti-inflammatory drugs in experimental atherosclerosis: 4. Inhibition of atherosclerosis in vivo and thromboxane synthesis and platelet aggregation in vivo. Atherosclerosis, 76, 155-161.
20. Naito, M., Yasue, M., Asai, K., Yamada, K., Hayashi, T., Kuzuya, M., Funai, C., Yoshimine, N., & Kuzuya, F. (1992). Effect of dexamethasone on experimental atherosclerosis in cholesterol-fed rabbits. J. Nutr. Sci. Vitaminol., 38, 255-264.
21. Paoletti, R., Bellosta, S., & Bernini, F. (1997). Pharmacological control of phagocyte function: inhibition of cholesterol accumulation. Ann. N.Y. Acad. Sci., 832, 322-329.
22. Pool, G. L., French, M. E., Edwards, R. A., Huang, L., & Lumb, R. H. (1982). Use of radiolabeled hexadecyl cholesterol ester as a liposome marker. Lipids, 17, 445-452.
23. Ross, R. (1993). The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature, 362, 801-809.
24. Ross, R. (1999). Atherosclerosis - an inframmtory disease. N. Engl. J. Med., 340, 115-126.
25. Ryu, B. H., Mao, F. W., Lou, P., & Gutman, R. L. (1995). Cholesterol ester accumulation in macrophages treated with oxidized low density lipoprotein. Biosci., Biotech. Biochem., 59, 1619-1622.
26. Tauchi, Y., Takase, M., Zushida, I., Chono, S., Sato, J., Ito, K., & Morimoto, K. (1999). Reparation of a complex of dexamethasone palmitate-low density lipoprotein and its effect on foam cell formation of murine peritoneal macrophages. J. Pharm. Sci., 88, 709-714.
27. Tauchi, Y., Zushida, I., Chono, S., Sato, J., Ito, K., & Morimoto, K. (2001). Effect of dexamethasone palmitate-low density lipoprotein complex on cholesterol ester accumulation in aorta of atherogenic model mice. Biol. Pharm. Bull., 24, 925-929.
28. Tauchi, Y., Yoshimi, A., Shirahase, H., Sato, J., Ito, K., & Morimoto, K. (2003). Inhibitory effect of acyl-CoA: cholesterol acyltransferase inhibitor-low density lipoprotein complex on experimental atherosclerosis. Biol. Pharm. Bull., 26, 73-78.
29. Tedgui, A., & Bernard, C. (1994). Cytokines, immuno-inframmatory response and atherosclerosis. Eur. Cytokine Network, 5, 263-270.
30. Van Put, D. J. M., Van Hove, C. E., De Meyer, G. R. Y., Wuyts, F., Herman, A. G., & Bult, H. (1995). Dexamethasone influences intima thickening and vascular reactivity in the rabbit collared carotid artery. Eur. J. Pharmacol., 294, 753-761.
31. Witztum, J. L., & Steinberg, D. (1991). Role of oxidized low density lipoprotein in atherosclerosis. J. Clin. Invest., 88, 1785-1792.
32. Yamaguchi, Y., Kitagawa, S., Imaizumi, N., Kunitomo, M., & Fujiwara, M. (1993). Enhancement of aortic cholesterol deposition by dietaary linoleic acid in cholesterol-fed mice: an animal model for primary screening of antiatherosclerotic agents. J. Pharmacol. Toxicol. Methods, 30, 169-175.
33. Yamaoka, K., Tanigawara, Y., Nakagawa, T., & Uno, T. (1981). A pharmacokinetic analysis program (MULTI) for microcomputer. J. Pharmacobio-dyn., 4, 879-890.
34. Yla-Herttuala, S., Palinski, W., Rosenfeld, M. E., Parthasarathy, S., Carew, T. E., Butler, S., Witztum, J. L., & Steinberg, D. (1989). Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabit and man. J. Clin. Invest., 84, 1086-1095.